After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Arbutus Biopharma Corp is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Arbutus Biopharma Corp is $707.92M. A total of 0.77 million shares were traded on the day, compared to an average of 1.02M shares.
In the most recent transaction, Sims Karen sold 4,358 shares of ABUS for 2.31 per share on Feb 02 ’24. After the transaction, the Chief Medical Officer now owns 125,542 company shares. In a previous transaction on Feb 02 ’24, HASTINGS DAVID C sold 9,593 shares at 2.31 per share. ABUS shares that Chief Financial Officer owns now total 181,907.
Among the insiders who sold shares, Sofia Michael J. disposed of 9,982 shares on Feb 02 ’24 at a per-share price of $2.31. This resulted in the Chief Scientific Officer holding 1,485,121 shares of ABUS after the transaction. In another insider transaction, McElhaugh Michael J. sold 10,164 shares at $2.31 per share on Feb 02 ’24. Company shares held by the Interim President & CEO now total 1,504,793.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, ABUS has a high of $3.98 and a low of $1.69.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. ABUS’s latest balance sheet shows that the firm has $155.32M in Cash & Short Term Investments as of fiscal 2021. There were $2.61M in debt and $11.22M in liabilities at the time. Its Book Value Per Share was $0.65, while its Total Shareholder’s Equity was $169.44M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ABUS is Buy with a score of 5.00.
